Decoding DDX41: Clinical impact of germline and somatic mutations in 77 high-risk myeloid neoplasm patients
Talha Badar(Mayo Clinic in Florida), Mrinal M. Patnaik(Mayo Clinic), Abhishek A. Mangaonkar(Mayo Clinic), Mohamed A. Kharfan‐Dabaja(Jacksonville College), Hemant S. Murthy(University of Florida), James M. Foran(Memorial Sloan Kettering Cancer Center), Timothy M. Chlon(Cincinnati Children's Hospital Medical Center), Hassan B. Alkhateeb(Mayo Clinic), Yael Kusne(WinnMed), Jennifer Jiang(European Society for Blood and Marrow Transplantation), Alejandro Ferrer(Mayo Clinic), Rong He(Mayo Clinic), Mahesh Kumar(European Society for Blood and Marrow Transplantation), Mark R. Litzow(Dana-Farber Cancer Institute), Yao‐Shan Fan(Jacksonville College), David S. Viswanatha(Mayo Clinic), Naseema Gangat(Mayo Clinic in Arizona), Terra Lasho(Toyota Motor Corporation (Switzerland)), Aref Al‐Kali(Mayo Clinic)
Cited by 1
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532